Journal
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
Volume 19, Issue 3, Pages 276-279Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00004347-200007000-00013
Keywords
ovary; endometriosis; ovarian adenocarcinoma; tamoxifen
Categories
Ask authors/readers for more resources
Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis. This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen. There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus. The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available